A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Tivozanib (Primary) ; Nivolumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms TiNivo
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 16 Oct 2017 According to an AVEO Oncology media release, phase 1 portion of the trial enrolled six patients and enrollment in the Phase 2 portion in ongoing.
    • 16 Oct 2017 According to an AVEO Oncology media release, data from the phase 1 part of this study will be presented at the 16th International Kidney Cancer Symposium.
    • 05 Oct 2017 According to AVEO Oncology media release, results from phase I portion of this study have been submitted for the presentation at the medical meeting taking place in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top